Transgene S.a annual ebitda margin
2021
2022
2023
2024
2025
Transgene S.a EBITDA Margin Growth & History (TNG)
Transgene S.a's ebitda margin was −467.86% for fiscal 2025.
View full Transgene S.a company overviewTransgene S.a annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −467.86% | +73.25 pp |
| 2024 | 2024-12-31 | −541.11% | −180.67 pp |
| 2023 | 2023-12-31 | −360.44% | −87.65 pp |
| 2022 | 2022-12-31 | −272.80% | −62.61 pp |
| 2021 | 2021-12-31 | −210.19% | — |
Transgene S.a ebitda margin trends
Between the periods ended 2021-12-31 and 2025-12-31, Transgene S.a's ebitda margin decreased from −210.19% to −467.86%, a change of −257.68 percentage points.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transgene S.a source filings ↗Community posts
Transgene reports €92.8 million in liquidity as vaccine development advances
Transgene ($TNG) reported €92.8 million in cash, cash equivalents and other current financial assets at its half-year end, compared with €111.9 million at the start of the year. First-half cash burn increased to €20.3 million from €18.8 mil ...
